Therapeutic vs Prophylactic LMWH Dosing
For treatment of established VTE, use therapeutic-dose LMWH (e.g., enoxaparin 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily), while for VTE prevention use prophylactic-dose LMWH (e.g., enoxaparin 40 mg once daily or 30 mg twice daily for high-risk surgical patients). 1, 2
Therapeutic Dosing Regimens
Treatment of Established VTE:
When treating confirmed deep vein thrombosis (DVT) or pulmonary embolism (PE), therapeutic anticoagulation is required. The 2022 International Clinical Practice Guidelines provide Grade 1A recommendations for LMWH as initial treatment when creatinine clearance is ≥30 mL/min 1.
Specific therapeutic doses include:
- Enoxaparin: 1 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily 2, 3
- Dalteparin: 200 IU/kg once daily initially, then reduced to 150 IU/kg once daily after 1 month for extended treatment 3, 2, 3
- Tinzaparin: 175 IU/kg once daily 2, 3
The guidelines recommend once-daily regimens unless twice-daily dosing is required due to bleeding risk, moderate renal failure, or need for technical intervention. When twice-daily regimens are needed, only enoxaparin 1 mg/kg twice daily should be used 1.
Prophylactic Dosing Regimens
VTE Prevention:
Prophylactic doses are substantially lower and designed to prevent rather than treat thrombosis.
For hospitalized medical patients:
- Enoxaparin: 40 mg once daily 2
- Dalteparin: 5,000 IU once daily 2
- Unfractionated heparin: 5,000 units every 8 hours 2
For surgical patients (cancer surgery):
- Enoxaparin: 40 mg once daily (or 30 mg twice daily in some protocols) 1, 2
- Dalteparin: 5,000 IU once daily 2
- Start 2-12 hours preoperatively and continue for at least 7-10 days 1
- Extended prophylaxis for 4 weeks is recommended after major abdominal or pelvic cancer surgery 1
The highest prophylactic dose of LMWH should be used for postoperative VTE prevention in cancer patients 1.
Key Dosing Distinctions
The fundamental difference is approximately 3-4 fold higher dosing for therapeutic versus prophylactic regimens. For example, enoxaparin prophylaxis uses 40 mg daily while therapeutic dosing uses 1 mg/kg twice daily (approximately 140-160 mg daily for a 70-80 kg patient).
Special Populations
Renal Impairment (CrCl <30 mL/min):
- Enoxaparin: Reduce to 1 mg/kg once daily for treatment; 30 mg once daily for prophylaxis 4, 3, 4
- Dalteparin and tinzaparin: May have less accumulation, but monitoring anti-Xa levels (target 0.5-1.5 IU/mL for treatment) is recommended 4
- Consider unfractionated heparin as alternative when LMWH is contraindicated 1
Obesity:
- Use total body weight for therapeutic dosing calculations 5
- Consider increased prophylactic doses in morbidly obese patients (BMI ≥40 kg/m²) 4, 5
- Weight-based prophylactic dosing (0.5 mg/kg every 12 hours) achieves goal anti-Xa levels more reliably than fixed dosing 6
Monitoring
Anti-Xa monitoring is generally not required but should be considered in:
- Severe renal impairment (CrCl <30 mL/min) 4
- Morbid obesity (weight >190 kg) 5
- Prolonged LMWH use (>10 days) with moderate renal impairment 5
Target anti-Xa levels:
- Prophylactic: 0.2-0.4 IU/mL 6
- Therapeutic: 0.5-1.5 IU/mL (measured 4-6 hours post-dose after 3-4 doses) 4
Common Pitfalls
Avoid these errors:
- Using prophylactic doses to treat established VTE—this is inadequate and risks treatment failure
- Failing to adjust enoxaparin in severe renal impairment—this significantly increases bleeding risk (2-3 fold) 3, 4
- Using tinzaparin in elderly patients (≥70 years) with renal insufficiency—associated with higher mortality 4
- Assuming all LMWHs are interchangeable—they differ pharmacologically and may require different dose adjustments 4, 3